BOHEE LEE

Prof. Dr. BOHEE LEE

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Health Expectations
Verified
Journal Article
Open access
EAEldad Agyei‐Manu
Eldad Agyei‐Manu
NANadege Atkins
Nadege Atkins
BLBohee Lee
Bohee Lee
JRJasmin Rostron
Jasmin Rostron
MDMarshall Dozier
Marshall Dozier
RMRuth McQuillan
Ruth McQuillan
Introduction: Despite the growing evidence on patient and public involvement (PPI) in health research, little emphasis has been placed on understanding its quality and appropriateness to evidence synthesis (ES) and systematic reviews (SR). This study aimed to synthesise qualitative evidence on the benefits, challenges, and best practices for PPI in ES/SR projects from the perspectives of patients/public and researchers.Methods: We searched Ovid MEDLINE, Ovid EMBASE, Cochrane Library and CINAHL Plus. We also searched relevant grey literature and conducted hand‐searching to identify qualitative studies which report the benefits and challenges of PPI in individual ES/SR projects. Studies were independently screened by two reviewers for inclusion and appraised using the Joanna Briggs Institute's Qualitative Tool. Included studies were synthesised narratively using thematic synthesis.Results: The literature search retrieved 9923 articles, of which eight studies were included in this review. Five themes on benefits emerged: two from patients'/public's perspective—gaining knowledge, and empowerment; and three from researchers' perspective—enhancing relevance, improving quality, and enhancing dissemination of findings. Six themes on challenges were identified: three from patients'/public's perspective—poor communication, time and low self‐esteem; and three from researchers' perspective—balancing inputs and managing relations, time, and resources and training. Concerning recommendations for best practice, four themes emerged: provision of sufficient time and resources, developing a clear recruitment plan, provision of sufficient training and support, and the need to foster positive working relationships.Conclusion: Highlighting the benefits and challenges of PPI in ES/SR projects from different stakeholder perspectives is essential to understand the process and contextual factors and facilitate meaningful PPI in ES/SR projects. Future research should focus on the utilisation of existing frameworks (e.g., Authors and Consumers Together Impacting on eVidencE [ACTIVE] framework) by researchers to help describe and/or report the best approaches and methods for involving patients/public in ES/SRs projects.Patient and Public Contribution: This review received great contributions from a recognised PPI partner, the Chair of the Cochrane Consumer Network Executive, to inform the final stage of the review (i.e., interpretation, publication and dissemination of findings). The PPI partner has been included as an author of this review.

11 November 2021 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
BLBohee Lee
Bohee Lee
SISiti Aishah Ibrahim
Siti Aishah Ibrahim
TZTiying Zhang
Tiying Zhang
Background: The COVID-19 pandemic increased attention to digital tools to support governmental public health policies in East and South-East Asia. Mobile apps related to the COVID-19 pandemic continue to emerge and evolve with a wide variety of characteristics and functions. However, there is a paucity of studies evaluating such apps in this region, with most of the available studies conducted in the early days of the pandemic. Objective: This study aimed to examine free apps developed or supported by governments in the East and South-East Asian region and highlight their key characteristics and functions. We also sought to interpret how the release dates of these apps were related to the commencement dates of other COVID-19 public health policies. Methods: We systematically searched for apps in Apple App Store and Google Play Store and analyzed the contents of eligible apps. Mobile apps released or updated with COVID-19–related functions between March 1 and May 7, 2021, in Singapore, Taiwan, South Korea, China (mainland), Japan, Thailand, Hong Kong, Vietnam, Malaysia, Indonesia, and the Philippines were included. The CoronaNet Research Project database was also examined to determine the timeline of public health policy commencement dates in relation to the release dates of the included apps. We assessed each app’s official website, media reports, and literature through content analysis. Descriptive statistics were used to summarize relevant information gathered from the mobile apps using RStudio. Results: Of the 1943 mobile apps initially identified, 46 were eligible, with almost 70% of the apps being intended for the general public. Most apps were from Vietnam (n=9, 20%), followed by Malaysia, Singapore, and Thailand (n=6 each, 13%). Of note, most apps for quarantine monitoring (n=6, 13%) were mandatory for the target users or a population subset. The most common function was health monitoring (32/46, 70%), followed by raising public health awareness (19/46, 41%) through education and information dissemination. Other functions included monitoring quarantine (12/46, 26%), providing health resources (12/46, 26%). COVID-19 vaccination management functions began to appear in parallel with vaccine rollout (7/46, 15%). Regarding the timing of the introduction of mobile solutions, the majority of mobile apps emerged close to the commencement dates of other public health policies in the early stages of the pandemic between March and April 2020. Conclusions: In East and South-East Asia, most governments used mobile health apps as adjuncts to public health measures for tracking COVID-19 cases and delivering credible information. In addition, these apps have evolved by expanding their functions for COVID-19 vaccination.

10 September 2025 in Thorax
Verified
Journal Article
Open access
PDF file
BLBohee Lee
Bohee Lee
DTDaira Trusinska
Daira Trusinska
SFSohail Ferdous
Sohail Ferdous
RPRuonan Pei
Ruonan Pei
HKHarley H Y Kwok
Harley H Y Kwok
TSTing Shi
Ting Shi
Background The long-acting monoclonal antibody nirsevimab and respiratory syncytial virus (RSV) vaccines became available for prevention of severe RSV-associated disease in 2023. While clinical trials showed good efficacy and safety, their restrictive inclusion criteria, small sample sizes and short follow-up limit generalisability. We aimed to summarise real-world evidence on the effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults. Methods A living systematic review and meta-analysis, with 5 monthly updated searches in three databases was performed. Eligible studies were published from 1 December 2022 to 10 March 2025. Meta-analyses for the effectiveness of nirsevimab and RSV vaccines were carried out using random-effects model. Safety data were summarised narratively. Results A total of 50 publications, covering approximately 7.6 million people, were included. Nirsevimab showed 80.7% effectiveness (95% CI: 75.7% to 85.7%; seven studies) against RSV-related emergency department visits, 80.7% (95% CI: 76.1% to 85.2%; 17 studies) against hospital admissions and 75.6% (95% CI: 63.3% to 87.9%; eight studies) against intensive care unit admissions. The effectiveness of RSV vaccines for older adults against RSV-related hospital admissions was 79.6% (95% CI: 73.8% to 85.3; three studies). No effectiveness data were available for RSV maternal vaccine. No severe adverse events were reported for nirsevimab, while RSV vaccines in older adults had fewer than 10 Guillain-Barré syndrome cases per million doses. No severe adverse events were reported for RSV maternal vaccine, although evidence was limited. Conclusions Our review demonstrated high effectiveness of nirsevimab in reducing RSV-related healthcare utilisation in infants and a favourable safety profile. More evidence is needed for evaluating RSV vaccines in pregnant people and older adults. PROSPERO registration number CRD42025643585.

17 January 2023 in Electronics
Verified
Journal Article
Open access
PDF file
HJhai young Jung
hai young Jung
Sugi ChoiSugi Choi
Sugi Choi
BLBOHEE LEE
BOHEE LEE
This study discusses a failure detection algorithm that uses frequency analysis and artificial intelligence to determine whether a rotor used in an industrial setting has failed. A rotor is a standard component widely used in industrial sites, and continuous friction and corrosion frequently result in motor and bearing failures. As workers inspecting failure directly are at risk of serious accidents, an automated environment that can operate unmanned and a system for accurate failure determination are required. This study proposes an algorithm to detect faults by introducing convolutional neural networks (CNNs) after converting the fault sound from the rotor into a spectrogram through STFT analysis and visually processing it. A binary classifier for distinguishing between normal and failure states was added to the output part of the neural network structure used, which was based on the transfer learning methodology. We mounted the proposed structure on a designed embedded system to conduct performance discrimination experiments and analyze various outcome indicators using real-world fault data from various situations. The analysis revealed that failure could be detected in response to various normal and fault sounds of the field system and that both training and validation accuracy were greater than 99%. We further intend to investigate artificial intelligence algorithms that train and learn by classifying fault types into early, middle, and late stages to identify more specific faults.

4 January 2024 in Electronics
Verified
Journal Article
Open access
PDF file
Sugi ChoiSugi Choi
Sugi Choi
BLBOHEE LEE
BOHEE LEE
JKJun Kim
Jun Kim
HJhai young Jung
hai young Jung
The accurate detection of P-wave FAP (First-Arrival Picking) in seismic signals is crucial across various industrial domains, including coal and oil exploration, tunnel construction, hydraulic fracturing, and earthquake early warning systems. At present, P-wave FAP detection relies on manual identification by experts and automated methods using Short-Term Average to Long-Term Average algorithms. However, these approaches encounter significant performance challenges, especially in the presence of real-time background noise. To overcome this limitation, this study proposes a novel P-wave FAP detection method that employs the U-Net model and incorporates spectrogram transformation techniques for seismic signals. Seismic signals, similar to those encountered in South Korea, were generated using the stochastic model simulation program. Synthesized WGN (White Gaussian Noise) was added to replicate background noise. The resulting signals were transformed into 2D spectrogram images and used as input data for the U-Net model, ensuring precise P-wave FAP detection. In the experimental result, it demonstrated strong performance metrics, achieving an MSE of 0.0031 and an MAE of 0.0177, and an RMSE of 0.0195. Additionally, it exhibited precise FAP detection capabilities in image prediction. The developed U-Net-based model exhibited exceptional performance in accurately detecting P-wave FAP in seismic signals with varying amplitudes. Through the developed model, we aim to contribute to the advancement of microseismic monitoring technology used in various industrial fields.

2 November 2022 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
BLBohee Lee
Bohee Lee
GLGrace Lewis
Grace Lewis
EAEldad Agyei-Manu
Eldad Agyei-Manu
NANadege Atkins
Nadege Atkins
UBUrmila Bhattacharyya
Urmila Bhattacharyya
ETEvropi Theodoratou
Evropi Theodoratou
Background: The Joint Committee on Vaccination and Immunisation in the United Kingdom requested an evidence synthesis to investigate the relationship between asthma and coronavirus disease 2019 (COVID-19) outcomes.Objective: We conducted a systematic review and meta-analysis to summarise evidence on the risk of severe COVID-19 outcomes in people with uncontrolled asthma or markers of asthma severity.Methods: High-dose inhaled corticosteroids (ICS) or oral corticosteroids (OCS) were used as markers of asthma severity, following international or national asthma guidelines. Risk of bias was assessed using Joanna Briggs Institute tools. Adjusted point estimates were extracted for random-effects meta-analyses and subgroup analyses.Results: After screening, 12 studies (11 in adults and one in children) met the eligibility criteria. Adults using high-dose ICS or OCS had a pooled adjusted hazard ratio (aHR) of 1.33 (95% CI 1.06–1.67, I2=0%) for hospitalisation and an aHR of 1.22 (95% CI 0.90–1.65, I2=70%) for mortality for COVID-19. We found insufficient evidence for associations between markers on COVID-19 mortality in the subgroup analyses.Conclusions: Adults with severe asthma are at increased risk of COVID-19 hospitalisation compared to nonusers. Our analysis highlighted the dearth of studies in children with asthma investigating serious COVID-19 outcomes.